- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A Novartis employee’s LinkedIn share and ‘like’ activity was found to promote POMs to the public and lacked certification. Breaches were ruled…
A UK health professional said prescribing information on PfizerPro for Xeljanz, Sutent and Champix was hard to read. Panel had some concerns…
PMCPA case AUTH/2905/11/16 (Director v A Menarini). Completed 7 March 2017. Outcome: No breach; matter considered outwith the scope of the ABPI…
At ESC Paris, a Bayer global staff party in a public hotel bar was attended by at least one UK health professional.…
A ViiV HCP website PDF omitted a newly added dolutegravir contraindication, leaving prescribing information inconsistent with the current SPC. Breaches of Clauses…
Two online press releases about investigational ASTX727 were circulated to UK outlets. Panel found misleading, unsubstantiated claims and failure to maintain high…
PMCPA found a senior executive’s personal LinkedIn post about Ampres 20mg/ml approval was accessible to the public, promoted a POM and was…
A Trelegy Ellipta web ad claimed “Improvement in quality of life vs ICS/LABA”. PMCPA ruled the comparison implied superiority vs all ICS/LABAs,…
Complaint alleged Repatha.co.uk promoted a POM to the public and used an overly broad CVD indication claim. Panel found audience separation and…
A 2012 Ventavis supply letter stored in a website “resource area” was discoverable via specific Google searches. PMCPA ruled it wasn’t “visible…
Daiichi-Sankyo admitted failing to disclose ~£857k transfers of value (therapy review service via third parties) for 2017–2019 on Disclosure UK, breaching its…
Two UK-based Takeda employees ‘liked’/shared a global LinkedIn post linking to Phase 3 data for investigational maribavir. No public POM promotion breach,…
Napp was accused of off-licence renoprotection claims and missing renal dosing/adult-only info in an Invokana webcast ad. Panel found the page linked…
Sanofi’s Toujeo DoubleStar slide deck claimed “fewer prescriptions”, a claim it had already agreed was unsubstantiated. PMCPA ruled it misleading and found…
Complaint about Chiesi’s respiratory website: alleged public advertising of POMs, weak HCP gating, vague “carer” wording, out-of-date videos and disparaging Nexthaler comments.…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.